In the United Kingdom, the COVID-19 vaccines were administered starting on December 8, 2020, and by May 6th, almost 39 million people there had received their first dose of the COVID-19 vaccine, with 24 million people receiving two doses, hence completely vaccinated. Given this data accumulation sufficient information was available for a review of the UK’s Yellow Card -based safety and adverse event reporting system. Recently, the Director of the Evidence-based Medicine Consultancy, Ltd and EbMC Squared CiC , Dr. Tess Lawrie wrote to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) with concerns about what appear to be accumulating adverse event data. For example, Dr. Lawrie raises the awareness that just between January 4, 2021 and May 26, 2021 a total of 1,253 deaths and 888,196 adverse events were reported, which aren’t directly proven as correlated with the vaccine process but most certainly could be so. So this means that in the real world about 4.5% of those that receive the vaccine could possibly have had an adverse event if these incidents are correlated to the jab. But that’s not proven here. Nonetheless, Lawrie has mounting concerns for people in the UK.

TrialSite was able to speak with Dr. Tess Lawrie about this letter and the expert in analyzing medical evidence definitely is concerned. She told TrialSite that “the total number of cases is concerning and that each person that’s reported should be followed up on to ensure there are no further problems. The scope of morbidity,” Lawrie declared, “is striking, evidencing a lot of incidents and what amounts to a large number of ill.”

What is the Yellow Card System?

Part of the regulatory agency known as the MHRA, the Yellow Card Scheme, is the UK’s system and method for identifying and collecting suspected adverse events associated with medicines or what they refer to in the UK as adverse drug reactions. This scheme was established to do exactly what Dr. Lawrie is now undertaking, to ensure that medicines and vaccines that make it to market are adequately monitored.

Lawrie told TrialSite the system is incredibly “opaque”, that is, not transparent. She shared that the researchers aren’t able to cross-reference safety incidents by age, gender, or other data attributes. She estimates that in the UK about 60%+ of all vaccines are AstraZeneca’s while the remainder from the mRNA-based Pfizer vaccine. There’s no way to tell which safety report is associated with which vaccine.

Health Consumers Need Transparency

TrialSite reminds that at least in the West, where market systems and choice are associated with healthcare, transparency and accessibility are of vital concern. Why? Because consumers/citizens themselves need to be able to understand any data and associated risk. This shouldn’t be monopolized by a few elites.  

Lead Research/investigator

TrialSite provides the letter to the MHRA from Dr. Lawrie here.

TrialSite Staff

trialsitenews.com

Read Source